Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients

BACKGROUND: Anti-CGRP monoclonal antibodies have shown notable effectiveness and tolerability in migraine patients; however, data on their use in elderly patients is still lacking, as clinical trials have implicit age restrictions and real-world evidence is scarce. In this study, we aimed to describ...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz-Vendrell, Albert, Campoy, Sergio, Caronna, Edoardo, Alpuente, Alicia, Torres-Ferrus, Marta, Nieves Castellanos, Candela, Olivier, Marina, Campdelacreu, Jaume, Prat, Joan, Camiña Muñiz, Javier, Molina Martínez, Francisco José, Mínguez-Olaondo, Ane, Ruibal Salgado, Marta, Santos Lasaosa, Sonia, Navarro Pérez, María Pilar, Morollón, Noemí, López Bravo, Alba, Cano Sánchez, Luis Miguel, García-Sánchez, Sonia María, García-Ull, Jésica, Rubio-Flores, Laura, Gonzalez-Martinez, Alicia, Quintas, Sonia, Echavarría Íñiguez, Ana, Gil Luque, Sendoa, Castro-Sánchez, María Victoria, Adell Ortega, Vanesa, García Alhama, Jessica, Berrocal-Izquierdo, Nuria, Belvís, Robert, Díaz-Insa, Samuel, Pozo-Rosich, Patricia, Huerta-Villanueva, Mariano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236648/
https://www.ncbi.nlm.nih.gov/pubmed/37268904
http://dx.doi.org/10.1186/s10194-023-01585-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236648/
https://www.ncbi.nlm.nih.gov/pubmed/37268904
http://dx.doi.org/10.1186/s10194-023-01585-2

Ejemplares similares